America Great Health (AAGH)
USD 0.0
(-18.18%)
USD 0.0
(-18.18%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -761.42 Thousand USD | 84.35% |
| 2022 | -4.86 Million USD | -1708.62% |
| 2021 | -269.05 Thousand USD | -418.25% |
| 2020 | -51.91 Thousand USD | 20.18% |
| 2019 | -65.04 Thousand USD | -9.53% |
| 2018 | -59.38 Thousand USD | 93.54% |
| 2017 | -918.66 Thousand USD | 19.48% |
| 2016 | -1.14 Million USD | -7233.55% |
| 2015 | -15.55 Thousand USD | 97.43% |
| 2014 | -605.61 Thousand USD | -456.63% |
| 2013 | -108.8 Thousand USD | -93.38% |
| 2012 | -56.26 Thousand USD | -155.45% |
| 2011 | -22.02 Thousand USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -247.69 Thousand USD | -58.4% |
| 2024 Q3 | -226.55 Thousand USD | 8.54% |
| 2024 Q1 | -156.37 Thousand USD | 35.32% |
| 2023 Q4 | -241.78 Thousand USD | -13.66% |
| 2023 FY | -761.42 Thousand USD | 84.35% |
| 2023 Q1 | -182.33 Thousand USD | 91.42% |
| 2023 Q2 | -124.56 Thousand USD | 31.68% |
| 2023 Q3 | -212.72 Thousand USD | -70.77% |
| 2022 Q2 | -1.8 Million USD | -443.68% |
| 2022 FY | -4.86 Million USD | -1708.62% |
| 2022 Q4 | -2.12 Million USD | -248.51% |
| 2022 Q3 | -609.53 Thousand USD | 66.16% |
| 2022 Q1 | -331.27 Thousand USD | -102.51% |
| 2021 Q3 | -13.41 Million USD | -36894.05% |
| 2021 Q4 | 13.18 Million USD | 198.28% |
| 2021 FY | -269.05 Thousand USD | -418.25% |
| 2021 Q1 | -2671.00 USD | 92.11% |
| 2021 Q2 | -36.26 Thousand USD | -1257.84% |
| 2020 FY | -51.91 Thousand USD | 20.18% |
| 2020 Q4 | -33.86 Thousand USD | -1135.46% |
| 2020 Q3 | -2741.00 USD | 75.44% |
| 2020 Q2 | -11.16 Thousand USD | -169.03% |
| 2020 Q1 | -4149.00 USD | 68.89% |
| 2019 Q4 | -13.33 Thousand USD | -77.11% |
| 2019 Q3 | -7531.00 USD | 79.39% |
| 2019 FY | -65.04 Thousand USD | -9.53% |
| 2019 Q1 | -7634.00 USD | 64.51% |
| 2019 Q2 | -36.54 Thousand USD | -378.65% |
| 2018 Q2 | -15.07 Thousand USD | -9.99% |
| 2018 FY | -59.38 Thousand USD | 93.54% |
| 2018 Q4 | -21.5 Thousand USD | -136.38% |
| 2018 Q3 | -9099.00 USD | 39.64% |
| 2018 Q1 | -13.7 Thousand USD | 71.66% |
| 2017 Q2 | -860.69 Thousand USD | -1384.81% |
| 2017 Q1 | -57.96 Thousand USD | 14.8% |
| 2017 Q3 | -12.12 Thousand USD | 98.59% |
| 2017 Q4 | -48.36 Thousand USD | -298.93% |
| 2017 FY | -918.66 Thousand USD | 19.48% |
| 2016 Q2 | -110.31 Thousand USD | -3130.37% |
| 2016 Q3 | -272.99 Thousand USD | -147.46% |
| 2016 Q1 | -3415.00 USD | 97.96% |
| 2016 Q4 | -68.03 Thousand USD | 75.08% |
| 2016 FY | -1.14 Million USD | -7233.55% |
| 2015 Q2 | -159.62 Thousand USD | -0.52% |
| 2015 Q4 | -167.34 Thousand USD | -5.39% |
| 2015 Q3 | -158.78 Thousand USD | 0.53% |
| 2015 Q1 | -158.79 Thousand USD | 60.7% |
| 2015 FY | -15.55 Thousand USD | 97.43% |
| 2014 Q3 | -151.69 Thousand USD | -204.05% |
| 2014 Q1 | -22.05 Thousand USD | 64.91% |
| 2014 Q4 | -404.03 Thousand USD | -166.35% |
| 2014 FY | -605.61 Thousand USD | -456.63% |
| 2014 Q2 | -49.89 Thousand USD | -126.22% |
| 2013 Q2 | -18.57 Thousand USD | -61.64% |
| 2013 Q4 | -62.84 Thousand USD | -350.0% |
| 2013 Q3 | -13.96 Thousand USD | 24.83% |
| 2013 Q1 | -11.49 Thousand USD | 76.61% |
| 2013 FY | -108.8 Thousand USD | -93.38% |
| 2012 Q2 | -2684.00 USD | -140.07% |
| 2012 Q3 | -4417.00 USD | -64.57% |
| 2012 Q1 | -1118.00 USD | 39.53% |
| 2012 Q4 | -49.12 Thousand USD | -1012.23% |
| 2012 FY | -56.26 Thousand USD | -155.45% |
| 2011 FY | -22.02 Thousand USD | 0.0% |
| 2011 Q4 | -1849.00 USD | -496.45% |
| 2011 Q3 | -310.00 USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Ampio Pharmaceuticals, Inc. | -8.63 Million USD | 91.179% |
| Aridis Pharmaceuticals, Inc. | -30.74 Million USD | 97.524% |
| Biora Therapeutics, Inc. | -124.11 Million USD | 99.387% |
| Bio-Path Holdings, Inc. | -16.07 Million USD | 95.264% |
| Better Therapeutics, Inc. | -39.76 Million USD | 98.085% |
| Calithera Biosciences, Inc. | -18.86 Million USD | 95.964% |
| Comera Life Sciences Holdings, Inc. | -18.37 Million USD | 95.857% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | -35.81 Million USD | 97.874% |
| Eloxx Pharmaceuticals, Inc. | -36.06 Million USD | 97.889% |
| Evelo Biosciences, Inc. | -114.52 Million USD | 99.335% |
| Evolutionary Genomics, Inc. | -2.24 Million USD | 66.133% |
| Finch Therapeutics Group, Inc. | -74.75 Million USD | 98.981% |
| Galera Therapeutics, Inc. | -59.08 Million USD | 98.711% |
| Innovation1 Biotech Inc. | -5.98 Million USD | 87.285% |
| Kiromic BioPharma, Inc. | -21.29 Million USD | 96.424% |
| Molecular Templates, Inc. | -8.12 Million USD | 90.628% |
| Navidea Biopharmaceuticals, Inc. | -15.17 Million USD | 94.983% |
| NexImmune, Inc. | -32.34 Million USD | 97.646% |
| Orgenesis Inc. | -55.36 Million USD | 98.625% |
| Panbela Therapeutics, Inc. | -25.26 Million USD | 96.986% |
| Point of Care Nano-Technology, Inc. | -78.01 Thousand USD | -875.967% |
| PaxMedica, Inc. Common Stock | -18.28 Million USD | 95.837% |
| Scopus BioPharma Inc. | -11.6 Million USD | 93.442% |
| Sorrento Therapeutics, Inc. | -572.84 Million USD | 99.867% |
| Statera Biopharma, Inc. | -174.4 Million USD | 99.563% |
| TRACON Pharmaceuticals, Inc. | -3.58 Million USD | 78.779% |
| Trevena, Inc. | -40.28 Million USD | 98.11% |
| Vaxxinity, Inc. | -56.93 Thousand USD | -1237.373% |
| Vaccinex, Inc. | -20.25 Million USD | 96.24% |
| Vicapsys Life Sciences, Inc. | -1.18 Million USD | 35.588% |
| Viracta Therapeutics, Inc. | -51.05 Million USD | 98.509% |
| ZIVO Bioscience, Inc. | -7.77 Million USD | 90.21% |